Q-omics provides the consensus-scored RPL6P8 profile across patient tissues and cancer cell-line models. RPL6P8 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPL6P8 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, RPL6P8 RNA expression shows 6,699 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight THCA, and PDAC as cancer lineages where RPL6P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL6P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL6P8 survival associations across molecular data types. RPL6P8 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL6P8 RNA expression–survival associations across cancer types. High RPL6P8 expression shows unfavorable associations in THCA, CHOL, THYM, LIHC and MESO, but favorable associations in ACC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RPL6P8 RNA expression.
This table summarizes RPL6P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL6P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL6P8 shows lower tumor expression in THCA and higher tumor expression in CHOL. The THCA box plot shows higher RPL6P8 RNA expression in normal versus tumor tissue (log2 FC = −0.028, t-test p = .005).
This table shows molecular features associated with RPL6P8 in patient tissues and cancer cell lines. In patient samples, RPL6P8 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
